Home › Funds › ING GROEP NV › VRTX
ING GROEP NV position in VRTX
VERTEX PHARMACEUTICALS INC · Health Care
ING GROEP NV reported holding 223,124 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$110.8M, representing 0.54% of its reported portfolio and ranking #36 among its reported holdings. ING GROEP NV has disclosed VRTX holdings in 10 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ING GROEP NV's VRTX position evolved
ING GROEP NV first disclosed a stake in VRTX in Q3 2023 at 85,158 shares (US$29.6M). The position peaked in Q2 2026 at 223,124 shares, worth US$110.8M. Across 10 filings, ING GROEP NV increased the stake 3 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 223,124 shares valued at US$110.8M — an increase of 157,699 shares quarter over quarter.. Notable position changes include a 91% trim in Q4 2024 (shares rose 20% over the following quarter), a 577% increase in Q4 2025 (shares fell 1% over the following quarter), a 241% increase in Q2 2026 (shares rose 5% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 85.16K | $29.61M | New |
| Q4 2023 | 75.10K | $30.56M | Reduce |
| Q1 2024 | 77.04K | $32.20M | Add |
| Q2 2024 | 66.12K | $30.99M | Reduce |
| Q3 2024 | 53.54K | $24.90M | Reduce |
| Q4 2024 | 4.78K | $1.93M | Reduce |
| Q3 2025 | 11.99K | $4.70M | New |
| Q4 2025 | 81.13K | $36.78M | Add |
| Q1 2026 | 65.42K | $29.21M | Reduce |
| Q2 2026 | 223.12K | $110.83M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VRTX and 13F data
VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 33 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$12.97B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VRTX
- Capital World Investors 26.12M sh · $12.97B · Q2 2026
- Capital World Investors 26.12M sh · $12.97B · Q2 2026
- Capital Research Global Investors 19.49M sh · $9.68B · Q2 2026
- Capital Research Global Investors 19.49M sh · $9.68B · Q2 2026
- Invesco Ltd 8.04M sh · $4.00B · Q2 2026
- LOOMIS SAYLES & CO L P 3.92M sh · $1.95B · Q2 2026
- JENNISON ASSOCIATES LLC 3.00M sh · $1.49B · Q2 2026
- ALLIANCEBERNSTEIN L.P. 3.02M sh · $1.35B · Q2 2026
- Clearbridge Investments, LLC 2.34M sh · $1.16B · Q2 2026
- VICTORY CAPITAL MANAGEMENT INC 2.17M sh · $1.08B · Q2 2026
- Janus Henderson Group 2.13M sh · $951.79M · Q1 2026
FAQ
How long has ING GROEP NV held VRTX?
ING GROEP NV has disclosed VRTX holdings in 10 of the last 12 reported quarters, going back to Q3 2023.
What is ING GROEP NV's current position in VRTX?
As of Q2 2026, ING GROEP NV holds 223.12K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $110.83M, representing 0.54% of its reported portfolio and ranking #36.
Has ING GROEP NV been buying or selling VRTX?
In the latest 13F filing (Q2 2026), ING GROEP NV increased its position in VRTX. The position peaked in Q2 2026 at 223.12K shares.
Which other funds hold VRTX?
Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 33 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.